Even in the context of already being treated with maximal doses of statins, PCSK9 inhibitors lowered plasma LDL-C levels by around 60%, PCSK9 inhibitors, unlike statins, do not result in serious adverse effects, including excessive myalgia, elevated plasma hepatic aminotransferase levels, diabetes mellitus, or neurocognitive adverse events (13). The gene discussed is PCSK9; the disease is diabetes mellitus.